Key Takeaways
- Haoxi Health Technology Ltd is raising approximately $4 million through a registered direct offering of 10 million Class A ordinary shares (or pre‑funded warrants) at $0.40 per share.
- The transaction is expected to close on or about July 13 2026, pending customary closing conditions, with Univest Securities, LLC acting as the sole placement agent.
- Net proceeds will be used for general corporate purposes, including working capital, potential acquisitions, and continued investment in the company’s marketing technology platform.
- Haoxi is a Beijing‑headquartered online‑marketing specialist serving healthcare advertisers, with a focus on short‑video ads on Douyin, Toutiao, WeChat, and Sina Weibo.
- Growth is driven by the rise of news‑feed advertising and the rapid expansion of China’s healthcare sector.
- The press release contains forward‑looking statements; actual results may differ, and investors should consult Haoxi’s SEC filings for risk factors.
Overview of the Registered Direct Offering
Haoxi Health Technology Ltd (NASDAQ: HAO) announced on July 10 2026 that it has entered into a definitive agreement with select investors for the purchase and sale of up to 10,000,000 of its Class A Ordinary Shares, each with a par value of $0.32, or alternatively pre‑funded warrants in lieu of the shares. The transaction is structured as a registered direct offering, meaning the securities are sold directly to institutional investors under an existing shelf registration statement. The purchase price is set at $0.40 per share, and the same price applies to the pre‑funded warrants after accounting for their exercise cost.
Share and Warrant Pricing Details
The purchase price for the pre‑funded warrants mirrors that of the ordinary shares, less the warrants’ exercise price of $0.33 per share. Consequently, investors who opt for the warrants effectively pay $0.07 per warrant upfront, with the right to acquire the underlying share later at the $0.33 exercise price. This structure provides flexibility for investors while preserving the same economic exposure to Haoxi’s equity as a direct share purchase. The company emphasized that the pricing reflects current market conditions and was negotiated in good faith with the participating investors.
Gross Proceeds and Intended Use
The aggregate gross proceeds to Haoxi from this offering are expected to be approximately $4 million, calculated from the sale of 10 million shares at $0.40 each. Although the press release does not specify a detailed use‑of‑proceeds plan, the company indicated that the funds will support general corporate purposes, including working capital, potential acquisitions, and continued investment in its marketing technology platform. Strengthening the balance sheet through this capital raise is intended to enable Haoxi to pursue growth opportunities in the rapidly expanding Chinese healthcare advertising market.
Expected Closing Date and Conditions
The transaction is slated to close on or about July 13 2026, pending the satisfaction of customary closing conditions. These conditions typically include receipt of any required regulatory approvals, completion of definitive documentation, and the absence of any material adverse changes affecting the company or the securities being offered. Haoxi and the investors have agreed to cooperate to fulfill these conditions promptly, aiming to ensure a smooth and timely completion of the offering.
Role of the Placement Agent
Univest Securities, LLC is acting as the sole placement agent for the registered direct offering. In this capacity, Univest is responsible for soliciting interest from qualified investors, structuring the transaction, and assisting with the preparation and filing of the necessary prospectus supplement. The firm’s expertise in capital markets and its existing relationship with Haoxi helped facilitate the negotiation of terms and the coordination of the closing process.
Shelf Registration and Prospectus
The offering is being made pursuant to a shelf registration statement on Form F‑3 (File No. 333‑287686) that Haoxi previously filed with the U.S. Securities and Exchange Commission (SEC) and which became effective on June 13 2025. A final prospectus supplement and accompanying prospectus detailing the terms of the offering will be filed with the SEC and made available on the SEC’s website at www.sec.gov. Electronic copies can be obtained, once available, by contacting Univest Securities at [email protected] or by calling +1 (212) 343‑8888.
Company Background and Headquarters
Haoxi Health Technology Limited is a Beijing‑headquartered enterprise that provides online marketing solutions specifically tailored to advertisers in the healthcare sector. Founded to capitalize on the digital transformation of medical services, the company leverages its local expertise and technology stack to serve clients across China’s major internet platforms. Its headquarters in Beijing situates it at the epicenter of the nation’s media and technology hub, facilitating close collaboration with platform partners and industry regulators.
Core Business and Healthcare Focus
The Company’s growth is driven by the rise of news feed advertisements and the rapid expansion of China’s healthcare industry. Haoxi concentrates on delivering marketing campaigns that reach patients, caregivers, and healthcare professionals through targeted digital channels. By aligning its services with the specific regulatory and cultural nuances of healthcare advertising, Haoxi helps clients navigate compliance while achieving measurable engagement and conversion metrics.
Service Portfolio and Platform Expertise
Haoxi offers a one‑stop online marketing suite, with particular strength in short‑video advertising on China’s leading short‑form platforms such as Douyin (the domestic version of TikTok), Toutiao, WeChat, and Sina Weibo. The suite includes creative development, audience targeting, bid management, performance analytics, and optimization services. This comprehensive approach enables advertisers to acquire new customers, retain existing ones, and maximize return on advertising spend across multiple touchpoints.
Mission: Cost Reduction, Efficiency, Easy Solutions
The company is dedicated to reducing costs, increasing efficiency, and providing easy‑to‑use online marketing solutions for its advertiser clients. By automating routine campaign tasks and leveraging data‑driven insights, Haoxi aims to lower the barrier to entry for sophisticated digital marketing, allowing even small‑to‑mid‑size healthcare brands to compete effectively in a crowded marketplace.
Growth Drivers: News Feed Ads and Healthcare Sector
The rise of news feed ads—native advertisements that appear within users’ content streams on platforms like Toutiao and Douyin—has created a fertile environment for Haoxi’s offerings. Simultaneously, China’s healthcare sector is experiencing double‑digit growth fueled by an aging population, increased health awareness, and government support for digital health initiatives. These twin trends provide a sustained tailwind for Haoxi’s revenue pipeline and strategic expansion plans.
Forward‑Looking Statements Disclaimer
Certain statements in this announcement are forward‑looking statements, reflecting the company’s current expectations about future events, financial performance, and strategic initiatives. These statements involve known and unknown risks and uncertainties, and actual results may differ materially from those anticipated. Haoxi cautions investors not to place undue reliance on such projections and notes that it will not update forward‑looking information except as required by law. Investors are encouraged to review the company’s SEC filings for a fuller discussion of risk factors.
Investor Relations Contact
For further information, investors may contact Haoxi’s Investor Relations team at [email protected]. The company’s press release, prospectus supplement, and related filings are accessible via the SEC’s website and through the placement agent’s channels.